Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.

ABSTRACT:

Background

Survival of patients with metastatic colorectal cancer (mCRC) has been significantly improved with the introduction of the monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). Novel molecular-targeted agents such as aflibercept and regorafenib have recently been approved. The aim of this review is to summarize and assess the effects of molecular agents in mCRC based on the available phase II and III trials, pooled analyses, and meta-analyses/systematic reviews.

Methods

A systematic literature search was conducted using the meta-database of the German Institute of Medical Documentation and Information. Criteria of the Scottish Intercollegiate Guidelines Network were used to assess the quality

SUBMITTER: Kirstein MM 

PROVIDER: S-EPMC4221380 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature